The CLL Research Consortium (CRC) is multi-institutional program, investigating the biologic basis of CLL and novel biologic and pharmacologic treatments for this disease, which enables CRC investigators to function beyond the capacities of any single member. It provides for uniform, high-volume sample accrual to a sophisticated national tissue bank, secured on-line information systems, and an infrastructure that facilitates the research on novel therapies and the evaluation of clinical-laboratory relationships that improve clinical staging and/or that assist in the early assessment of response to novel therapies. The CRC has six major projects. Project 1 investigates the genetic basis for CLL and the development of novel probes that can translate genetic discoveries into the clinic. Project 2 investigates the leukemia cell expression of proteins that regulate susceptibility to apoptosis and novel compounds that can interfere with their biochemical function. Project 3 examines for leukemia-associated antigens and novel techniques for active immunotherapy of this disease, including gene therapy. Project 4 examines the mechanism(s) accounting for ineffective T cell mediated immune response against putative leukemia-cell antigens and evaluates for specific T cell defects that can interfere with development of effective anti-tumor cellular immune responses. Project 5 focuses on promising anticancer agents for phase l/ll testing in patients with CLL and examines the activity of these agents acting alone or in mechanism-based combinations. Project 6 is a new project that examines the pharmacology of promising new agents for treatment of this disease. The CRC has 4 cores: The administrative core coordinates research investigations, oversees the generation and maintenance of the clinical and laboratory databases and information systems, and facilitates information and data exchange between program participants. The Biostatistics Core assists investigators in the design and interpretation of basic and clinical research. The Tissue Core is responsible for tissue banking, sample trafficking, and leukemia-sample laboratory testing and sample-validation. The Clinical Core helps develop, implement, execute, monitor, and analyze CRC clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA081534-11
Application #
7802158
Study Section
Subcommittee G - Education (NCI)
Program Officer
Wu, Roy S
Project Start
1999-05-01
Project End
2012-04-30
Budget Start
2010-05-01
Budget End
2012-04-30
Support Year
11
Fiscal Year
2010
Total Cost
$4,044,476
Indirect Cost
Name
University of California San Diego
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Hasan, M K; Yu, J; Chen, L et al. (2017) Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells. Leukemia 31:2615-2622
Patel, V M; Balakrishnan, K; Douglas, M et al. (2017) Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199). Leukemia 31:1872-1881
Patel, Viralkumar; Balakrishnan, Kumudha; Bibikova, Elena et al. (2017) Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells. Clin Cancer Res 23:3734-3743
Edelmann, J; Tausch, E; Landau, D A et al. (2017) Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial. Leukemia 31:734-738
Miller, Cecelia R; Ruppert, Amy S; Fobare, Sydney et al. (2017) The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia. Oncotarget 8:25942-25954
Vangapandu, Hima V; Jain, Nitin; Gandhi, Varsha (2017) Duvelisib: a phosphoinositide-3 kinase ?/? inhibitor for chronic lymphocytic leukemia. Expert Opin Investig Drugs 26:625-632
Vangapandu, Hima V; Chen, Huiqin; Wierda, William G et al. (2017) Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells. Leuk Lymphoma :1-12
Rassenti, Laura Z; Balatti, Veronica; Ghia, Emanuela M et al. (2017) MicroRNA dysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 114:10731-10736
Kipps, Thomas J; Stevenson, Freda K; Wu, Catherine J et al. (2017) Chronic lymphocytic leukaemia. Nat Rev Dis Primers 3:16096
Vangapandu, Hima V; Havranek, Ondrej; Ayres, Mary L et al. (2017) B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia. Mol Cancer Res 15:1692-1703

Showing the most recent 10 out of 552 publications